Protective effect of hydroxysafflor yellow A on Parkinson cell model and its network pharmacology analysis

doi:10.5246/jcps.2020.12.078

Abstract

Abstract:

As an effective component of safflower, hydroxysafflor yellow A (HSYA) has the effect of promoting blood circulation, removing blood stasis, and relieving pain, and it has a certain effect on blood stasis and wind-induced Parkinson’s disease (PD). However, the current research mostly involves a single intervention mechanism, which is not conducive to the clinical transformation of this type of drugs. In the present study, rotenone was used to construct a PD cell model, and the protective effect of HSYA on the PD cell model was evaluated by cell viability and mitochondrial membrane potential. TTD database was used to query PD-related therapeutic targets, Swiss Target Prediction database to query HSYA-related targets, STRING database was used to search the gene interaction relationship of common targets, and ClueGO pathway was adopted to enrich and analyze common targets and their interaction targets, as well as to explore the comprehensive intervention mechanism. The results showed that rotenone could successfully establish the PD cell model, and HSYA had significant protective effect on PD cell model. Through the network pharmacological analysis, 36 PD-related therapeutic targets and 88 HSYA-related targets were queried. The common targets of PD and HSYA were FKBP1A, HTR1A, SLC6A4 and SLC6A3. To enrich four common targets and their interaction targets through REACTOME pathway, eight cell signal pathways were obtained, and six cell biological processes were obtained through biological process pathway enrichment.

Key words: Hydroxysafflor yellow A, Parkinson's disease, Network pharmacology

Supporting:

Shuang Li, Chunyan Guo, Shuangshuang Li, Sihan You, Xiujuan Yu. Protective effect of hydroxysafflor yellow A on Parkinson cell model and its network pharmacology analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(12): 880-895.

Figures/Tables 11

Table 1. PD-related therapeutic targets.

Table 2. HSYA-related therapeutic targets.

Table 3. Possible targets of HSYA intervention in PD.

References 37

[1]	Binde, C.D.; Tvete, I.F.; Gåsemyr, J.I.; Natvig, B.; Klemp, M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur. J. Clin. Pharmacol. 2020, 76, 1731–1743.
[2]	Chang, Y.M.; Manoj Kumar, M.; Lu, C.Y.; Te Tsai, C.; Tsai, C.C.; Liao, P.H.; Lin, S.L.; Chang, C.C.; Mahalakshmi, B.;Kuo, W.W.; Huang, C.Y. Parkinson’s disease a futile entangle ofMankind's credence on an herbal remedy: a review. LifeSci. 2020, 257, 118019.
[3]	Chen, X.W.; Ren, C.P.; Li, J.;Wang, S.P.; Dron, L.; Harari, O.; Whittington, C. The efficacy andsafety of piribedil relative to pramipexole for the treatment of earlyparkinson disease: a systematic literature review and network meta-analysis. Clin.Neuropharmacol. 2020, 43, 100–106.
[4]	di Martino, R.M.C.; Pruccoli, L.;Bisi, A.; Gobbi, S.;Rampa, A.; Martinez, A.; Pérez, C.; Martinez-Gonzalez, L.; Paglione, M.; di Schiavi, E.;Seghetti, F.; Tarozzi, A.; Belluti, F. Novel curcumin-diethyl fumarate hybridas a dualistic GSK-3β inhibitor/Nrf2inducer for the treatment of Parkinson’s disease. ACS Chem. Neurosci. 2020, 11, 2728–2740.
[5]	Jankovic, J.;Tan, E.K. Parkinson’s disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry. 2020, 91, 795–808.
[6]	Kamel, W.A.;Al-Hashel, J.Y. LCIG in treatment of non-motor symptoms in advanced Parkinson’sdisease: Review of literature. Brain Behav. 2020, 10, e01757.
[7]	Group, P.M.C. Long-term effectiveness of dopamine agonists and monoamine oxidase Binhibitors compared with levodopa as initial treatment for Parkinson’s disease(PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014, 384, 1196–1205.
[8]	Gu, C.; Shen, T.; An, H.M.; Yuan, C.X.; Zhou, J.; Ye, Q.; Liu, T.; Wang, X.W.;Zhang, T.L. Combined therapy of Di-Huang-Yi-Zhi withDonepezil in patients with Parkinson’s disease dementia. Neurosci. Lett. 2015, 606, 13–17.
[9]	Chen, H.Z.; He, J.C.; Teng, L.; Yuan, C.X.; Zhang, Z. Traditional ChineseMedicine symptom pattern analysis for Parkinson’s disease. J. Tradit. Chin. Med. 2017, 37, 688–694.
[10]	Li, X.L.; Zhang, Y.N.; Wang, Y.; Xu, J.; Xin, P.; Meng, Y.H.;Wang, Q.H.; Kuang, H.X. Themechanisms of traditional Chinesemedicine underlying the prevention and treatmentof Parkinson’s disease. Front. Pharmacol. 2017, 8, 634.
[11]	Zhang, J.S.; Zhang, Z.N.; Bao, J.; Yu, Z.H.; Cai, M.; Li, X.T.; Wu, T.; Xiang, J.; Cai, D.F. Jia-Jian-Di-Huang-Yin-Zi decoction reduces apoptosis induced by both mitochondrial and endoplasmic reticulumcaspase12 pathways in the mouse model of Parkinson's disease. J. Ethnopharmacol. 2017, 203, 69–79.
[12]	Jiang, Y.N.; Guo, Y.Z.; Lu, D.H.; Pan, M.H.; Liu, H.Z.; Jiao, G.L.; Bi, W.;Kurihara, H.; Li, Y.F.; Duan, W.J.; He, R.R.; Yao, X.S. Tianma Gouteng granulesdecreases the susceptibility of Parkinson’s disease by inhibiting ALOX15-mediated lipid peroxidation. J. Ethnopharmacol. 2020, 256, 112824.
[13]	Yang, J.F.; Wang, R.; Cheng, X.H.; Qu, H.C.; Qi, J.; Li, D.; Xing, Y.; Bai, Y.H.; Zheng, X.D.The vascular dilatation induced by Hydroxysafflor yellow A (HSYA) on ratmesenteric artery through TRPV₄-dependentcalcium influx in endothelial cells. J. Ethnopharmacol. 2020, 256, 112790.
[14]	Wu, L.; Tang, Y.P.; Shan, C.X.;Chai, C.; Zhou, Z.; Shi, X.Q.; Ding, N.; Wang, J.Y.; Lin, L.P.; Tan, R.X. Acomprehensive in vitro and in vivo metabolism study of hydroxysaffloryellow A. J.Mass Spectrom. 2018, 53, 99–108.
[15]	Ni, B.; Zhou, D.L.; Jing, Y.Y.; Liu, S.X. Hydroxysafflor yellow A protects against angiotensin II-induced hypertrophy. Mol. Med. Rep. 2018, 18, 3649–3656.
[16]	Huber, G.A.; Priest, S.M.;Geisbuhler, T.P. Cardioprotective effect ofhydroxysafflor yellow A via the cardiac permeability transitionpore. PlantaMed. 2018, 84, 507–518.
[17]	Jin, M.; Wang, L.; Wu, Y.; Zang, B.X.; Tan, L. Protective effect of hydroxysafflor yellow Aon bleomycin- inducedpulmonary inflammation and fibrosis in rats. Chin. J. Integr. Med. 2018, 24, 32–39.
[18]	Yan, L. Inhibitory effect of thecombination of notoginseng totalsaponins and safflower total flavonoids onUDP-glucuronosyltransferases 1A1, 1A4, and 2B7 in human liver microsomes. J. Chin. Pharm. Sci. 2019, 28, 229–237.
[19]	Zheng, M.;Guo, X.J.; Pan, R.Y.; Gao, J.W.; Zang, B.X.; Jin, M. Hydroxysafflor yellow Aalleviates ovalbumin-induced asthma in a Guinea pig model by attenuateing theexpression of inflammatory cytokines and signal transduction. Front. Pharmacol. 2019, 10, 328.
[20]	Dong, F.; Xue, C.J.; Wang, Y.; Peng, Y.Y.; Zhang, Y.D.; Jin, M.; Zang, B.X.Hydroxysafflor yellow A attenuates the expression of inflammatory cytokines inacute soft tissue injury. Sci.Rep. 2017, 7, 40584.
[21]	Liu, L.; Si, N.; Ma, Y.C.; Ge, D.Y.; Yu, X.; Fan, A.R.; Wang, X.; Hu, J.H.; Wei, P.; Ma, L.; Chen, Z.W.; Zhang, Q.; Feng, C.L. Hydroxysafflor-yellow Ainduces human gastric carcinoma BGC-823 cell apoptosis by activating peroxisome proliferator-activated receptor gamma (PPARγ). Med.Sci. Monit. 2018, 24, 803–811.
[22]	Yu, L.; Liu, Z.L.; He, W.D.; Chen, H.F.; Lai, Z.L.; Duan, Y.H.; Cao, X.H.; Tao, J.; Xu, C.; Zhang, Q.J.; Zhao, Z.; Zhang, J. Hydroxysafflor yellow Aconfers neuroprotectionfrom focal cerebral ischemia by modulating the crosstalk between JAK₂/STAT₃ and SOCS₃ signaling pathways. Cell. Mol. Neurobiol. 2020, 40, 1271–1281.
[23]	Hu, M.Z.; Zhou, Z.Y.; Zhou, Z.Y.; Lu, H.; Gao, M.; Liu, L.M.; Song, H.Q.; Lin, A.J.; Wu, Q.M.; Zhou, H.F.; Li, L.; Wang, X.; Cai, Y.F. Effect and safety of hydroxysafflor yellow A for injection inpatients with acute ischemic stroke of blood stasis syndrome: a phase II, multicenter, randomized, double-blind, multiple-dose, active-controlled clinical trial. Chin. J. Integr.Med. 2020, 26, 420–427.
[24]	Zhou, D.L.; Ding, T.T.; Ni, B.; Jing, Y.Y.; Liu, S.X. HydroxysafflorYellow A mitigated myocardial ischemia/reperfusion injuryby inhibiting the activation of the JAK₂/STAT₁ pathway. Int. J. Mol. Med. 2019, 44, 405–416.
[25]	Cheng, S.X. Preparation and characterization of drop pillsof effective part from safflower for anti-Parkinson’s disease. J. Chin. Pharm. Sci. 2019, 28, 27–39.
[26]	Haider, S.; Madiha, S.; Batool, Z. Amelioration of motor and non-motor deficits andincreased striatal APoE levels highlight the beneficial role of pistachio supplementation in rotenone-induced rat model of PD. Metab. Brain Dis. 2020, 35, 1189–1200.
[27]	Zahra, W.; Rai, S.N.; Birla, H.; Singh, S.S.; Rathore, A.S.; Dilnashin, H.;Singh, R.; Keswani, C.; Singh, R.K.; Singh, S.P. Neuroprotection ofrotenone-induced Parkinsonism by ursolic acid in PD mouse model. CNS Neurol. Disord. Drug Targets. 2020, 19, 527–540.
[28]	Hedya, S.A.; Safar, M.M.; Bahgat, A.K. Cilostazol mediatedNurr1and autophagy enhancement: neuroprotective activity in rat rotenone PD model. Mol. Neurobiol. 2018, 55, 7579–7587.
[29]	Li, L.T.; Qiu, H.Y.; Liu, M.M.; Cai, Y.M. A network pharmacology-basedstudy of the molecular mechanisms of Shaoyao-Gancao decoction intreating Parkinson’s disease. Interdiscip.Sci. Comput. Life Sci. 2020, 12, 131–144.
[30]	Li, J.Q.; Zhou, Y.Z.; Du, G.H.; Qin, X.M.; Gao, L. Integration of transcriptomics and networkanalysis deciphers the mechanisms ofbaicalein in improving learning and memoryimpairment in senescence-accelerated mouseprone 8 (SAMP8). Eur.J. Pharmacol. 2019, 865, 172789.
[31]	Li, J.Q.;Zhou, Y.Z.; Du, G.H.; Qin, X.M.; Gao, L. Bioinformatic analysis reveals key genes and pathways inaging brain of senescence-accelerated mouse P8 (SAMP8). CNS Neurol.Disord. - Drug Targets. 2018, 17, 712–722.
[32]	Wang, C.; Ren, Q.; Chen, X.T.; Song, Z.Q.; Ning, Z.C.; Gan, J.H.; Ma, X.L.; Liang, D.R.; Guan, D.G.; Liu, Z.L.; Lu, A.P. System pharmacology-basedstrategy to decode the synergistic mechanism of Zhi-Zhu wan for functional dyspepsia. Front. Pharmacol. 2018, 9, 841.
[33]	Liu, X.G.; Cheng, C.Y.; Wang, J.X.; Luo, H.; Tu, L.F.; Lin, L.; Wu, B.; Wang, H.Y.; Liu, K.; Li, P.; Yang, H. A metabolic exposure-orientednetwork regulation strategyfor the identification of effective combination in the extract of Ginkgo bilobaL. J. Pharm. Biomed.Anal. 2018, 149, 151–159.
[34]	Anitha, P.; Anbarasu, A.; Ramaiah, S. Gene network analysis reveals theassociation of important functional partners involved in antibiotic resistance:a report on an important pathogenic bacterium Staphylococcus aureus. Gene. 2016, 575, 253–263.
[35]	Wang, Y.; Fu, X.; Xu, J.; Wang, Q.H.; Kuang, H.X. Systems pharmacology to investigate theinteraction of berberine and other drugs in treating polycystic ovary syndrome. Sci. Rep. 2016, 6, 28089.
[36]	Pan, R.Y.; Zhang, Y.D.; Zheng, M.; Zang, B.X.; Jin, M. Hydroxysafflor yellow A suppresses MRC-5 cell activation induced by TGF-β₁ by blocking TGF-β₁ binding to TβRII. Front.Pharmacol. 2017, 8, 264.
[37]	Han, B.; Wang, L.J.; Fu, F.H.; Wang, Z.H.; Zhang, L.M.; Qi, G.J.; Wang, T. Hydroxysafflor yellow A promotes α-synucleinclearance via regulating autophagy in rotenone-induced Parkinson’sdisease mice. Folia Neuropathol. 2018, 56, 133–140.